MiR-138 inhibits proliferation by targeting 3-phosphoinositide-dependent protein kinase-1 in non-small cell lung cancer cells

Clinical Respiratory Journal

Volumn 9, Issue 1, 2015, Pages 27-33

  Ye, Xian wei ^a,b   Yu, Hong ^a,b   Jin, Yan kun ^a,b   Jing, Xiao ting ^a,b   Xu, Mei ^a,b   Wan, Zi fen ^a,b   Zhang, Xiang yan ^a,b  

^a GUIZHOU PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b Academic Department Guizhou Institute of Respiratory Diseases   (China)

Author keywords

3 phosphoinositide dependent protein kinase 1; Cell proliferation; MiR 138; Non small cell lung cancer; siRNA

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 138; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE; MIRN138 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CULTURE TECHNIQUE; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASES; CARCINOMA, NON-SMALL-CELL LUNG; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LUNG NEOPLASMS; MICRORNAS; RNA, MESSENGER;

EID: 84923264333     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/crj.12100     Document Type: Article

References (25)

1. Ardizzoni A, Boni L, Tiseo M, etal. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99(11): 847-857.
2. Scagliotti GV, Parikh P, von Pawel J, etal. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21): 3543-3551.
3. Boyero L, Sanchez-Palencia A, Miranda-Leon MT, etal. Survival, classifications, and desmosomal plaque genes in non-small cell lung cancer. Int J Med Sci. 2013;10(9): 1166-1173.
4. Shaoyan X, Juanjuan Y, Yalan T, etal. Downregulation of EIF4A2 in non-small-cell lung cancer associates with poor prognosis. Clin Lung Cancer. 2013;14(6): 658-665. pii: S1525-7304(13)00079-X.
5. Vendetti FP, Rudin CM. Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases. Expert Opin Biol Ther. 2013;13(9): 1273-1285.
6. Ding L, Getz G, Wheeler DA, etal. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455(7216): 1069-1075.
7. Weir BA, Woo MS, Getz G, etal. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007;450(7171): 893-898.
8. Shedden K, Taylor JM, Enkemann SA, etal. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008;14(8): 822-827.
9. Li Y, Yang KJ, Park J. Multiple implications of 3-phosphoinositide dependent protein kinase 1 in humancancer. World J Biol Chem. 2010;1(8): 239-247.
10. Fyffe C, Falasca M. 3-Phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer. Cancer Manag Res. 2013;23(5): 271-280.
11. Alessi DR, James SR, Downes CP, etal. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997;7(4): 261-269.
12. Liu D, Huang Y, Chen B, etal. Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma. Cancer. 2011;117(16): 3763-3773.
13. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2): 281-297.
14. Griffiths-Jones S. miRBase: microRNA sequences and annotation. Curr Protoc Bioinformatics. 2010 Chapter 12: Unit 12.9.1-10.
15. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2007;96(Suppl): R40-44.
16. Maatouk D, Harfe B. MicroRNAs in development. Sci World J. 2006;26(6): 1828-1840.
17. Crawford M, Brawner E, Batte K, etal. MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun. 2008;373(4): 607-612.
18. Zhang JG, Wang JJ, Zhao F, etal. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta. 2010;411(11-12): 846-852.
19. Ceppi P, Mudduluru G, Kumarswamy R, etal. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res. 2010;8(9): 1207-1216.
20. Chen Z, Zeng H, Guo Y, etal. miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res. 2010;29: 151-155.
21. Takahashi Y, Forrest AR, Maeno E, etal. MiR-107 and MiR-185 can induce cell cycle arrest in human non-small cell lung cancer cell lines. PLoS ONE. 2009;4(8): e6677.
22. Zhang JG, Guo JF, Liu DL, etal. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J Thorac Oncol. 2011;6(4): 671-678.
23. Zhang H, Zhang H, Zhao M, etal. MiR-138 inhibits tumor growth through repression of EZH2 in non-small cell lung cancer. Cell Physiol Biochem. 2013;31(1): 56-65.
24. Mora A, Komander D, van Aalten DM, Alessi DR. PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol. 2004;15(2): 161-170.
25. Golubovskaya VM, Sumbler B, Ho B, Yemma M, Cance WG. MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells. Anticancer Agents Med Chem. 2013;14(1): 18-28. Feb 15. [Epub ahead of print].